Documents

A list of downloadable documents created during development.

Ovarian cancer, fallopian tube and primary peritoneal cancer (recurrent advanced) - bevacizumab equality impact assessment - guidance review - May 2013

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appraisal consultation

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - final scope

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - final matrix

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: equality impact assessment form - scoping

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - draft scope for consultation (pre-referral) - May 2011

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - provisional matrix (pre-referral) - May 2011